Kevin Davies

Izpisúa Belmonte, PhD, Altos Labs, advocates a disease-agnostic approach, but first, he said, “we must understand the mechanism, something that is core to the cell.”

Intellia CSO Birgit Schultes, PhD, provided an update on three ongoing clinical programs at ESGCT 2025.

He described how we move forward to increase the use of CRISPR in the clinic and how to streamline the process by which this can happen.

Bacteria and their phage, “are full of mysteries and also lots of really powerful mechanisms that we can study and potentially harness.”

Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary roundtable conducted by the FDA in front of its recently-appointed top officials.

This week a group of researchers, bioethicists, publishers and theologians are discussing the merits of human heritable genome editing.

Mike McCune said the Gates Foundation is “doubling down” on finding a cure for HIV during an ASGCT symposium.

After an illustrious career, including 12 years as director of the NIH and leading the HGP consortium, Francis Collins announces his sudden resignation.

After an illustrious career, including 12 years as director of the NIH and leading the HGP consortium, Francis Collins announces his sudden resignation.

The CRISPR-SCD trial is the first clinical attempt to use a non-viral delivery approach to directly correct the sickle cell disease mutation.

An editorial by Fyodor Urnov, PhD, lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

Among the newer initiatives was developing the lab of the future; next-gen biology; AI and sustainability. The new facility would tackle major challenges including CAR-T manufacturing. Also, reducing the variability of viral vectors, scalability, safety and efficacy.

After more than a decade of effort, researchers report the identification and extensive testing of a small-molecule drug candidate that has the potential to treat sickle cell patients by boosting the levels of fetal hemoglobin.

In one of the opening workshops at ASGCT 2024, topics around delivery methods for gene therapies and approaches to expand the gene editing toolbox dominated the discussion. The quality of the presentations bodes well for a busy week in Baltimore.

Investigators have published and presented exciting clinical results in dozens of treated patients with sickle cell disease.

A Swiss team led by Mandy Boontanrart, PhD, has devised a clever permutation on the gene switching strategy currently progressing in the clinic to compensate for the faulty beta globin gene in the famous hereditary blood disorder.

In an exemplary keynote address by David Liu, the developer of base and prime editing salutes the rapid uptake of “CRISPR 2.0” editing technologies around the world, as indicated by a succession of encouraging preclinical studies.

In 1981, Genetic Engineering and Biotechnology News launched as the newspaper of record for the fledgling biotechnology industry. Publications come and go, but GEN has stayed the course for the past 40 years, providing authoritative coverage of news, research trends and technologies that are driving the field. Over that time, GEN’s parent company (Mary Ann […]

On the centenary of her birth, a look back at the fundamental role of Rosalind Franklin in unraveling the structure of the double helix in 1953. Her contributions were barely acknowledged at the time and her character tarnished 15 years later in Jim Watson’s chauvinistic bestseller, The Double Helix. Thankfully, Franklin’s pivotal role in the double helix drama has been restored.

Scientists and patients preach medical progress at “Unite to Cure”, held at the Vatican.